Nephros Inc (NEPH) · Nov 5, 2026 · Earnings

Nephros earnings beat estimates as gross margin slips

Beat — Diluted EPS $0.05 vs ~$0.02 consensus; revenue $5.62M vs ~$5.49M

Nephros earnings beat Q3 revenue and EPS expectations, extending its growth streak while gross-margin pressure and tariff effects complicate the picture.

Nephros is a small, commercial-stage water-filtration company expanding from its healthcare base into commercial applications while layering service and education onto its product business. Its 2025 strategy emphasized an integrated product, service and education model, and second-quarter 2026 results had already established a record-revenue growth trajectory.

The quarter beat a modest published bar. Revenue of $5.62 million exceeded the published consensus of approximately $5.49 million, while diluted EPS of $0.05 was well above the roughly $0.02 estimate. The beat is real, but the comparison is thin: the available consensus covered only one estimate, so this is better viewed as continued execution above a low bar than as a major reset of expectations.

Q3 2026Q3 2025Consensus
Total net revenue (Income Statement)$5.62M (+18%)$4.76M~$5.49M
Diluted EPS (Income Statement)$0.05$0.03~$0.02
Operating income (Income Statement)$0.50M (+59%)$0.31M
Gross margin (Financial discussion)58% (-3 pts)61%

Profitability improved despite a weaker margin rate. Operating income rose to $0.5 million and the company remained profitable, showing that revenue growth is converting into earnings even as gross margin fell to 58% from 61%. Higher shipping, handling and tariff costs, plus a larger mix of lower-margin service revenue, are putting pressure on the economics of each sales dollar. 〔0〕

The quality of growth is mixed rather than uniformly accelerating. Total revenue grew 18%, but programmatic product revenue grew only 8% in the quarter, with emergency-response revenue providing a meaningful contribution. That makes the headline growth stronger than the most repeatable core-product trend, although the installed base reached a record 1,766 sites and healthcare still supplied most new locations. 〔1〕

The nine-month earnings picture includes a temporary boost. Gross margin for the first nine months benefited from approximately $0.6 million of tariff refunds, including about $0.3 million tied to inventory converted to revenue in 2026. That benefit supports reported profitability but makes the underlying margin trend less clean, especially alongside currency, tariff and mix pressures.

Bottom line: Nephros delivered a genuine earnings beat and is still scaling revenue, customers and operating profit. The result modestly strengthens the growth story, but falling gross margins and reliance on emergency-response revenue keep it from being a decisive upgrade.

What to watch next

Q4 2026 results

Original filing on SEC EDGAR

More Nephros Inc news

Nephros earnings beat estimates as gross margin slips | NEPH Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.